Section
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.
This review synthesizes evidence on testicular endocrine function in boys undergoing treatment for hematological malignancies, highlighting reversible dysfunctions, Sertoli cell maturation delay, and the need for long-term endocrine surveil
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Routine DAT offers limited additional clinical value over transcutaneous bilirubin monitoring in low-risk ABO and RhD-incompatible neonates, supporting guideline shifts towards selective DAT use and emphasizing maternal antibody screening.
This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall
The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.
The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien
Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.
Septic shock following allogeneic hematopoietic stem-cell transplantation has a high 90-day mortality rate of 63%, strongly influenced by illness severity, fungal infection, and neutropenia. Early aminoglycoside use shows complex associatio
Cheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlighting
Distinct CAR architectures in tisa-cel (4-1BB costimulation) and axi-cel (CD28 costimulation) influence mechanisms of resistance through CD19 loss, affecting relapse rates in B-cell malignancies treated with CD19-CAR-T therapies.
Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.
The GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.
This multicenter study reveals that recent mechanical venous thrombosis risk factors markedly increase the risk of cryptogenic ischemic stroke in young adults, especially in those under 40 and with patent foramen ovale, independent of throm
This multicenter study reveals that recent mechanical venous thrombosis risk factors within 14 days significantly increase the risk of cryptogenic ischemic stroke in young adults, notably in those under 40 and with patent foramen ovale, ind
This study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.
Baseline plasma levels of CPVL and PIGR correlate with anthracycline-induced systolic dysfunction, offering potential early biomarkers for cardiotoxicity in hematologic malignancy patients undergoing chemotherapy.
Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.
DNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.
